TRANSCRIPTION: This is Cynthia Matossian of Matossian Eye Associates. Dry eye disease is ubiquitous. We have better means of diagnosing it and even broader options to treat dry eye disease. Some of the new pharmaceutical products include the following 4 products to treat dry eye disease. All of these are prescription.
- We have RESTASIS, which has been around for almost 20 years.
- We have Xiidra, lifitegrast, which also has been around now for quite some years.
- The newest kid on the block is CEQUA, which is also a cyclosporine with NCELL technology to help penetrate with some micron molecules, which are about 22 nanometers in diameter, enhancing penetration.
- And the last prescription product in this group is Klarity C, which is also a cyclosporine product with chondroitin sulfate.
So as physicians now, we have the option to prescribe one of these 4 products when there’s inflammation as a component in a particular patient’s dry eye disease. We’re fortunate to have these options, and they are available and on a prescription basis.
Video Credit: Bullseye Media
